GlassScriptPhysician profile
Dennis E Morrisroe
NPI 1659553741
$5,064.27
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,424 · 2020: $1,479 · 2021: $1,879 · 2022: $254 · 2023: $28.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $870.00 | 2019-2022 | |
| Abbvie INC. | $669.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $413.63 | 2019-2022 | |
| Pfizer INC. | $388.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $371.06 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $345.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.55 | 2019-2021 | |
| Novo Nordisk INC | $181.61 | 2019-2021 | |
| Amarin Pharma, INC. | $181.13 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $160.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $157.78 | 2019-2022 | |
| Allergan, INC. | $146.73 | 2019-2020 | |
| Astellas Pharma US INC | $112.39 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $83.08 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $78.37 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $77.34 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $76.40 | 2019-2021 | |
| Daiichi Sankyo INC. | $66.89 | 2020-2021 | |
| Esperion Therapeutics, INC. | $49.94 | 2020-2021 | |
| Glaxosmithkline, LLC. | $48.72 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $42.39 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.95 | 2019-2020 | |
| Gilead Sciences, INC. | $39.94 | 2019-2021 | |
| Lilly USA, LLC | $29.22 | 2019-2020 | |
| Organon LLC | $28.81 | 2023 | Nexplanon |
| Teva Pharmaceuticals USA, INC. | $27.27 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $25.91 | 2021 | |
| Ironshore Pharmaceuticals INC. | $24.25 | 2020 | |
| Sanofi Pasteur INC. | $19.76 | 2019 | |
| Hologic Sales and Service, LLC | $18.80 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.80 | 2020 | |
| Medtronic Minimed, INC. | $15.85 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.13 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.83 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Morrisroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.